SCG Cell Therapy links up with A*STAR's BTI on cancer research

Singapore-based biotech SCG Cell Therapy Pte has signed a collaboration agreement with A*STAR’s Bioprocessing Technology Institute (BTI) to advance the development of multi-specific antibodies.

The collaboration will leverage BTI’s multi-specific antibody technology platform and SCG’s product development expertise for novel therapeutic antibody screening and chemistry, manufacturing and control (CMC) process development to discover new treatment candidates for infectious diseases and related cancers, particularly the hepatitis B virus (HBV) and human papillomavirus (HPV). Such treatments could complement and augment existing drugs and result in more effective, safer and affordable treatments for patients.

Frank Wang Shuli, chief executive of SCG Cell Therapy, said: “We’re pleased to sign our first partnership with BTI, a world-class research institute and further strengthening our ties with A*STAR, supporting its vision to position Singapore as a key global bio-manufacturing and biomedical R&D hub.